NETWORK RISKS AMONG INJECTING DRUG USERS

注射吸毒者的网络风险

• 批准号: 6523656
• 负责人: ALAN NEAIGUS
• 金额: $ 7.05万
• 依托单位: NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6523656
• 关键词: African; American; European; behavioral /social science research tag; blood tests; clinical research; disease /disorder proneness /risk; drug abuse; hepatitis C virus; high risk behavior /lifestyle; human immunodeficiency virus; human subject; injection /infusion; international cooperation; interpersonal relations; public health; questionnaires; racial /ethnic difference; saliva; sex behavior; sexually transmitted diseases; social behavior; statistics /biometry; substance abuse epidemiology; substance abuse related behavior; young adult human (21-34)

DESCRIPTION (provided by applicant): In many countries, new injecting drug users (IDUs) are at substantial risk of becoming infected with HIV and hepatitis C (HCV). New IDUs are at increased risk of infection if their risk networks (i.e., the people with whom they use drugs or have sex) and social influence networks (i.e., the people with whom they interact and who influence their behavior) are high risk. Understanding how network and behavioral risks for infection among new injectors vary cross-nationally is essential to the development of international and local public health policies and preventive interventions to combat the AIDS and HCV epidemic among IDUs. Comparative studies of new IDUs in different countries can contribute to an understanding of how cross-national differences in the social and drug using environment and cultural contexts can influence the network and behavioral risks of new IDUs. This proposal is submitted to obtain a R03 grant for exploratory international research that will involve a collaboration between Dr. Alan Neaigus of the National Development and Research Institutes, in New York City, and Dr. Anne Lovell of the National Institute of Health and Medical Research (INSERM), U 379, in Marseilles, France. The purpose of the research is to examine network and behavioral risks for HIV and HCV infection among new IDUs (those who started to inject drugs within the last 6 years and who are from 18 to 30 years of age). The study will conduct preliminary analyses of survey and HIV and HCV test data from ongoing studies of IDUs in New York and Marseilles to compare the network and behavioral risks of new IDUs in the two cities. Qualitative research using institutional and ethnographic data will also be conducted to explore the extent to which differences in the drug use and social benefit environments affect new injectors' network and behavioral risk. Since there are many IDUs of North African origin in Marseilles, the study will also conduct exploratory research to understand whether transnational travel patterns between Southern France and North Africa by IDUs of North African origin are related to their network and behavioral risks for HIV and HCV. Findings from the preliminary analyses of the survey and biological data and from the exploratory qualitative research will be used to generate hypotheses and to develop the conception and design of a future larger scale study of new injectors in the two cities that will be submitted as an RO1 application.

描述（由申请人提供）：在许多国家，新注射吸毒者 (IDU) 面临着感染艾滋病毒和艾滋病毒的巨大风险。 丙型肝炎（HCV）。如果新注射吸毒者的风险 网络（即与他们一起吸毒或发生性关系的人）和社交 影响网络（即与他们互动并影响他们的人） 他们的行为）是高风险的。了解网络和行为风险如何 新注射者之间的感染情况在不同国家之间存在差异，这对于 制定国际和地方公共卫生政策和预防措施 抗击注射吸毒者中艾滋病和丙型肝炎病毒流行的干预措施。比较 对不同国家的新注射吸毒者的研究有助于了解 社会和吸毒环境的跨国差异如何 文化背景会影响新注射吸毒者的网络和行为风险。 提交本提案是为了获得探索性国际研究的 R03 拨款 该研究将涉及 Alan Neaigus 博士与 纽约市国家发展和研究机构和安妮博士 洛弗尔，美国国家健康与医学研究所 (INSERM) 379，法国马赛​​。研究的目的是检验网络 新注射吸毒者（那些吸毒者）中 HIV 和 HCV 感染的行为风险 过去 6 年内开始注射毒品且年龄在 18 至 30 岁之间 年龄）。该研究将对调查以及 HIV 和 HCV 进行初步分析 纽约和马赛正在进行的注射吸毒者研究的测试数据进行比较 两个城市新注射吸毒者的网络和行为风险。定性 还将利用机构和人种学数据进行研究 探讨药物使用和社会效益的差异程度 环境影响新注射者的网络和行为风险。由于有 马赛有许多来自北非的注射吸毒者，该研究还将进行 探索性研究以了解跨国旅行模式是否 法国南部和北非之间由北非裔注射吸毒者进行的 与他们的网络和行为风险有关的艾滋病毒和丙型肝炎病毒。 调查和生物数据的初步分析结果 探索性定性研究的结果将用于生成假设 并制定未来更大规模新研究的构想和设计 两个城市的注射器将作为 RO1 申请提交。